α-GalCer and MPL |
|
Vaxjo ID |
307 |
|
Vaccine Adjuvant Name |
α-GalCer and MPL |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
α-Galactosylceramide is described as a Natural Killer T Cell Ligand, and monophosphoryl lipid A (MPL) is described as a TLR4 ligand. They are evaluated as an efficient adjuvant combination for cancer vaccine. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Natural Killer T Cell Ligand α-Galactosylceramide(α-GalCer) adjuvants |
|
Preparation |
The combination of α-GalCer and MPL was co-administered with an HPV-16 E7 DNA vaccine. |
|
Function |
we evaluated whether co-administration of a TLR4 ligand, monophosphoryl lipid A (MPL), and Natural Killer T Cell Ligand 娄脕-Galactosylceramide(α-GalCer) adjuvants with DNA vaccine would influence the anti-tumor efficacy of DNA vaccinations |
|
Safety |
The study focuses on efficacy in tumor protection in mice, not on human safety profiles. |
| Related Vaccine(s) |
|
| References |
Gableh et al., 2016: Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, Ghaemi A. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. Journal of biomedical science. 2016; 23; 16. [PubMed: 26811064].
|
